TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced its participation in a virtual fireside chat at the LifeSci 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced its participation in a virtual fireside chat at the LifeSci 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:00 a.m. ET. The event will focus on T-cell receptor (TCR) engineered therapies aimed at treating cancer. Interested parties can access a live webcast via the company’s website, with an archived replay available for 30 days post-event. TScan specializes in innovative TCR-T therapies, including candidates TSC-100 and TSC-101 targeting hematologic malignancies.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +5.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the LifeSci 2nd Annual Genetic Medicines Symposium on Tuesday, June 28, 2022, at 9:00 a.m. ET.
A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at www.ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead leukemia TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
Contacts:
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.